secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001193125-24-160292
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen CEO Tony Hunt to become Executive Chair; Olivier Loeillot appointed President and CEO effective Sept 1, 2024
--------------------------------------------------------------------------------

- Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
- Loeillot, currently President & Chief Commercial Officer (since Oct 2023), will join the Board.
- Current Board Chair Karen Dawes becomes Lead Independent Director effective Sept 1, 2024.
- Under Hunt's 9-year tenure, Repligen revenue grew from ~$63M (2014) to $639M (2023), ~30% CAGR.
- Loeillot has ~30 years industry experience, previously Bioprocess President at Cytiva.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312524160292/0001193125-24-160292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312524160292/d126737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-160292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer